Health information needs and preferences in relation to survivorship care plans of long-term cancer survivors in the American Cancer Society’s Study of Cancer Survivors-I

Purpose

Survivorship care plans (SCPs) provide cancer patients and health care providers with a treatment summary and outline of recommended medical follow-up. Few studies have investigated the information needs and preferred sources among long-term cancer survivors.

Methods

Cancer survivors of the ten most common cancers enrolled in the longitudinal Study of Cancer Survivors-I (SCS-I) completed a survey 9 years post-diagnosis (n?=?3138); at time of diagnosis of the SCS-I cohort, SCPs were not considered usual care. We assessed participants’ current desire and preferred sources for information across ten SCP items and evaluated factors associated with information need 9 years after diagnosis.

Results

The proportion of long-term cancer survivors endorsing a need for cancer and health information 9 years post-diagnosis ranged from 43 % (cancer screening) to 9 % (consequences of cancer on ability to work). Print media and personalized reading materials were the most preferred information sources. Younger age, higher education, race other than non-Hispanic white, later cancer stage, having breast cancer, having ≥2 comorbidities, and self-reporting poor health were associated with greater informational need (p?<?0.05).

Conclusions/Implications for Cancer Survivors

Long-term cancer survivors continue to report health information needs for most SCP items and would prefer a print format; however, level of need differs by socio-demographic and cancer characteristics. Cancer survivors who did not previously receive a SCP may still benefit from receiving SCP content, and strategies for enabling dissemination to long-term survivors warrant further investigation.

     

Milestones in Mission: the Work of the American Cancer Society’s Mission Delivery

Since its founding in 1913, the American Cancer Society (the Society) has played a prominent role in the fight against cancer. Through its presence in over 5,000 communities around the nation, the Society has explored and pursued innovative ideas, searched for breakthroughs, and pushed to have the nation understand the complexities of the disease. Ongoing assessment of the cancer problem, thoughtful strategic planning, and promotion of evidence-based cancer control programs are integral to the Society’s mission. This paper provides a summary of these efforts.     

Epidemiology of Lymphedema-related admissions in the United States: 2012–2017

BackgroundLymphedema is a debilitating chronic condition with no definitive curative treatment. There is a paucity of data on prevalence, mortality and burden of care in the United States. This study aimed to describe hospitalizations due to lymphedema and identify factors associated with poor outcomes.Study designWe performed a retrospective analysis of the Healthcare Cost and Utilization Project National Inpatient Sample for lymphedema-related hospitalizations from 2012 to 2017. All adults admitted with a primary diagnosis of lymphedema or a primary diagnosis of extremity cellulitis and secondary diagnosis of lymphedema were included. Weights were used to obtain national estimates and complex sampling structure was accounted for using survey methods. Chi-squared tests were performed to assess the association between patient demographics, hospital characteristics, and inpatient mortality.ResultsBetween 2012 and 2017, there were an estimated 165,055 lymphedema admissions in the United States. The vast majority of hospitalizations were for cellulitis (92%), lower extremity disease (88%), and were admitted through the emergency room (77%). Median length of stay was 3.61 days (IQR 2.24–5.77) and inpatient mortality was 0.03% (n = 505). Age >80yrs (OR 3.83, 95% CI 1.72, 8.52) and Charlson comorbidity index ≥3 (OR 4.13, 95% CI 2.19, 7.79) were associated with increased risk of inpatient mortality.ConclusionAlthough mortality is low, lymphedema-related hospitalizations are a significant burden to the US healthcare system. Counseling older lymphedema patients with comorbidities on early symptoms and signs of infection and prompt treatment of same may reduce mortality.     

Highlights of the American Society of Clinical Oncology Annual Meeting 2005 13–17 May, 2005, Florida,USA

In the past few years, major improvements and new technologies have been proposed and applied in esophageal surgery. Its evolution depended not only on a thorough knowledge of surgical anatomy and technique, but also on important developments in pre- and postoperative care. Esophageal resection for cancer is still associated with high morbidity and mortality. Postoperative complications may be either patient or surgeon related. Patient-related factors include age, malnutrition, immunodepression and associated diseases. The surgeon-related factors are surgical experience, hospital volume and multidisciplinary approach. Preoperative evaluation is defined as the process of clinical assessment that precedes the delivery of anesthesia. The principle is to gain information concerning patients that leads to modification of their management, and improves the outcome from surgery.     

Oncology providers’ evaluation of the use of an automatically generated cancer survivorship care plan: longitudinal results from the ROGY Care trial

Purpose

Previous studies have merely investigated oncology providers’ a priori attitudes toward SCPs. The purpose of the current study was to longitudinally evaluate oncology providers’ expectations and actual experiences with the use of an automatically generated Survivorship Care Plan (SCP) in daily clinical practice.

Methods

Between April 2011 and October 2012, the participating oncology providers (i.e., gynecologists, gynecologic oncologists, oncology nurses) provided usual care or SCP care to 222 endometrial and 85 ovarian cancer patients included in the Registrationsystem Oncological GYnecology (ROGY) Care trial. All (n?=?43) oncology providers in both arms were requested to complete a questionnaire before and after patient inclusion regarding their expectations and evaluation of SCP care.

Results

Before patient inclusion, 38 (88 %; 21 SCP, 17 usual care), and after patient inclusion, 35 (83 %; 20 SCP, 15 usual care) oncology providers returned the questionnaire. After patient inclusion, oncology providers were generally satisfied with the SCP (M?=?7.1, SD?=?1.3, with 1?=?not at all–10?=?very much) and motivated to keep using the SCP (M?=?7.9, SD?=?1.5). Most providers (64 %) encountered barriers. Twenty-five percent felt they used more time for consultations (M?=?7.3 min, SD?=?4.6). However, self-reported consultation time did not differ between before (M?=?21.8 min, SD?=?11.6) and after patient inclusion (M?=?18.7, SD?=?10.6; p?=?0.22) or between SCP care (M?=?18.5, SD?=?10.3) and usual care (M?=?22.0, SD?=?12.2; p?=?0.21).

Conclusions

Oncology providers using the SCP were generally satisfied and motivated to keep using the SCP. However, the findings of the current study suggest that even when the SCP can be generated automatically, oncology providers still have difficulties with finding the time to discuss the SCP with their patients.

Implications for Cancer Survivors

If SCP care is indeed effective, overcoming the perceived barriers is needed before large-scale implementation in order for cancer survivors to fully benefit from the potential advantages of SCPs.     

The Effects of Time to Treatment Initiation for Patients With Non–small-cell Lung Cancer in the United States

BackgroundThe purpose of this study was to determine the effects of time from diagnosis to treatment (TTI) on survival in patients with nonmetastatic non–small-cell lung cancer (NSCLC).Materials and MethodsThe National Cancer Database was queried for patients with stages 1 to 3 NSCLC between 2004 and 2013. Patients with missing survival status/time, unknown TTI, or receipt of palliative therapy were excluded. Multivariable Cox proportional hazards modeling, logistic regression, and recursive partitioning analysis were performed to determine associated variables and survival outcomes.ResultsAltogether, 1,393,232 patients met inclusion criteria. The median follow-up was 36 months. The median TTI increased between 2004 and 2013 from 35 to 39 days (P < .001). On multivariable Cox proportional hazards modeling, TTI groups 31 to 60 days, 61 to 90 days, and > 90 days were independently related to poorer overall survival (OS) compared with TTI 1 to 30 days (hazard ratio, 1.04, 1.10, and 1.14; 95% confidence interval [CI], 1.02-1.06, 1.07-1.12, and 1.11-1.17, respectively; P < .001 for all). Recursive partitioning analysis revealed that TTI of ≤ 45 days was the most optimal threshold for survival (P < .001); patients with TTI ≤ 45 days had a median OS of 70.2 months (95% CI, 69.3-71.1 months) versus 61.5 months (95% CI, 60.5-62.4) (P < .001). There were significant disparities by age, race, ethnicity, and income for delayed (> 45 days) TTI (P < .001 for all). Subgroup analysis revealed that stage 1 and 2 patients with TTI > 45 days had a higher risk of mortality compared with TTI ≤ 45 days (hazard ratio, 1.15 and 1.05; 95% CI, 1.12-1.17 and 1.01-1.09, respectively) (P < .001).ConclusionsIncreased TTI is independently associated with poorer survival in non-metastatic NSCLC. TTI ≤ 45 days is a clinically targetable time frame associated with improved outcomes and ought to be considered for patients with lung cancer undergoing definitive therapy.     

Is the incidence of invasive vulvar cancer increasing in the United States?

Objective  

To document incidence rates of vulvar cancer, specifically invasive vulvar cancer, from 1973 to 2004 in the United States.